About the Company
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKBA News
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablets for the treatment of ...
After a struggle, Akebia’s oral CKD drug is approved by the FDA
After a complete response letter (CRL) from the U.S. FDA in 2022 and approvals in Europe, Japan and Australia, Akebia ...
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at ...
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
Akebia's Vafseo finally gets its shot at US chronic kidney disease market after FDA approval
Akebia never lost confidence in its oral chronic kidney disease (CKD) anemia drug Vafseo, even after the FDA nixed its first ...
Akebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis Patients
Akebia Therapeutics Inc. (AKBA) said that the U.S. Food and Drug Administration has approved Vafseo or vadadustat Tablets for the ...
Akebia stock jumps as FDA clears renal anemia therapy
Akebia Therapeutics (AKBA) receives FDA approval for Vafseo tablets, leading to a 25% surge in premarket shares.
Two years after initial rejection, Akebia’s anemia drug finally gets FDA approval
Two years after Akebia Therapeutics received a rejection letter from the U.S. Food and Drug Administration over a drug it ...
Akebia’s CKD Anemia Drug Ends Tough Regulatory Path with FDA Approval
After an initial rejection due to safety issues, followed by a dispute and deferred actions, Akebia Therapeutics on Wednesday ...
Akebia’s Vafseo gains FDA approval for anaemia due to CKD
The US FDA has granted approval for Akebia Therapeutics' Vafseo tablets for anaemia caused by chronic kidney disease (CKD).
Akebia joins GSK in US market for oral CKD anaemia drugs
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in ...
Akebia Awaits FDA Word On Second Crack At Vadadustat
An FDA decision looms for Akebia Therapeutics and its proposed vadadustat treatment for anemia due to chronic kidney disease in adults on dialysis. The FDA, which turned away Akebia's initial ...
Loading the latest forecasts...